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Figure 1 - BMT Collected - Median TNC Count v Median CD34+ 
Cell Count 
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Figure 2 - PBPC Collected - Median TNC Count v Median CD34+ 
Cell Count 
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Figure 3 - BMT Transplanted - Median TNC Count v Median CD34+ 
Cell Count 
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Figure 4 - PBPC Transplanted - Median TNC Count v Median 
CD34+ Cell Count 
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Jamie A. Thurman-Newell, Dr Jon Petzing and Professor David J.  Williams[a] 
 
[a]Healthcare Engineering Group, Centre for Biological Engineering, Loughborough University, Holywell Park, Loughborough University, LE11 3TU 
Median TNC Count (x10 , LOG10 scale) 
Median TNC nt (x106, LOG10 scale) 
Median TNC Count (x106, LOG10 scale) 
Median TNC Count (x106, LOG10 scale) 
M
ed
ia
n
 C
D
3
4
+
 C
el
l 
C
o
u
n
t 
(x
1
0
6
, 
L
O
G
1
0
 s
ca
le
) 
M
ed
ia
n
 C
D
3
4
+
 C
el
l 
C
o
u
n
t 
(x
1
0
6
, 
L
O
G
1
0
 s
ca
le
) 
M
ed
ia
n
 C
D
3
4
+
 C
el
l 
C
o
u
n
t 
(x
1
0
6
, 
L
O
G
1
0
 s
ca
le
) 
M
ed
ia
n
 C
D
3
4
+
 C
el
l 
C
o
u
n
t 
(x
1
0
6
, 
L
O
G
1
0
 s
ca
le
) 
Figure 3: Transplanted BMT Figure 4: Transplanted PBPC 
Figure 2: Collected PBPC 
Figure 1: Collected BMT 
Using blood and blood-based products as a case study, this project will investigate and seek to manage 
biological input variation from a processing perspective by relating this to clinical outcome (i.e. patient 
benefit) and exploring the concerns due to input variation when manufacturing a biological therapeutic at 
multiple sites. 
 
• Hematopoietic stem cell transplants are used to treat blood-based cancer and immunological deficiency 
• Over 130,000 transplants were carried out in Europe between 1990 and 2000[1] 
• The living cell is the product, introducing more complexity and sensitivity than found in pharmaceuticals 
• Humans are the source of the raw material, and we are inherently variable 
• Variation affects the cost, the safety of the therapeutic and the efficacy of the treatment 
Strategies for dealing with variation will derive from mapping the contributions of each step (see below) in 
the process and determining their sensitivity. By isolating the greatest sources of variation, the list of difficult 
problems can be reduced and can inform where time and money should be invested to address this issue. The 
three stages to this are measuring, explaining and stratifying.  
 
• A systematic search of the literature was carried out for bone marrow & peripheral blood using PRISMA[2] 
• This focused on donor characteristics and collected/transplanted cell populations 
• A demonstration of the results are shown in Figures 1 to 4 
• Each point on the graph represents the median TNC and CD34 positive cell count for an individual study 
• ‘Error bars’ show the range of the recorded cell numbers, and represent the variation 
A critical drawback of this study is that it is based on an incomplete dataset that is limited by the information 
published in the literature.  
 
• Important donor characteristics such as gender, weight and ethnicity were rarely reported 
• Protocols, techniques and equipment were also sporadically reported 
• However, Figures 1 to 4 demonstrate the scope of the problem 
• The biological variation in blood based products can be up to four orders of magnitude of the median 
• The current process may be adding variation up to two orders of magnitude 
 
A more complete dataset is essential to corroborating these findings. 
The key outcomes of this project will be strategies for handling complexity in manufacturing and product 
development consequent from input variation, incorporating measurement precision, for living products. 
  
1. Establish a complete database and applying this database to a therapeutic application (GSK) 
2. Map the contributions of input material to clinical outcome (Dana Farber Cancer Institute[4] and GSK) 
3. Retrospectively study the trend in biological precision over time to predict the future trend 
4. Addressing the issue of measurands  (the ‘CD34 Issue’[3]) 
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